BLTE · Belite Bio, Inc

Belite Bio has reached a significant regulatory milestone by initiating a rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant, an investigational novel oral therapy for Stargardt disease type 1 (STGD1). This submission is supported by data from the pivotal Phase 3 DRAGON trial, which demonstrated tinlarebant's impact on slowing retinal degeneration in adolescent subjects. The drug candidate has secured multiple regulatory designations, including Breakthrough Therapy Designation (BTD), Fast Track, and Orphan Drug status in the U.S., which may facilitate an expedited review process. Stargardt disease is a rare, inherited retinal disorder with no currently approved treatments; thus, a successful approval would represent a first-in-class therapeutic option for patients. The Company expects to complete the rolling submission in the second quarter of 2026 and is actively building out its commercial infrastructure, including sales, market access, and medical affairs teams, to prepare for a potential launch next year. This event marks a critical transition from late-stage clinical development to the regulatory approval phase for the company's lead asset.